http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2542229-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_805f4bd39d68467aa2b25dfec0900b0e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C11D1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662 |
| filingDate | 2001-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a51662ee53c5a6895bcaded422bc6489 |
| publicationDate | 2015-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2542229-T3 |
| titleOfInvention | Formulation containing phosphate derivatives of electronic transfer agents |
| abstract | A formulation for use as a therapeutic product, wherein the formulation comprises: (a) a mixture of at least one phosphate derivative of a monoelectronic transfer agent and at least one phosphate derivative of a dielectronic transfer agent; where the electronic transfer agent is selected from the group consisting of hydroxychromans, stumps and tocotrienols in enantiomeric and racemic forms; quinoles which are the reduced forms of vitamin K1 and ubiquinone; and hydroxycarotenoids; and where the molar ratio between the phosphate derivative of the monoelectronic transfer agent and the phosphate derivative of the dielectronic transfer agent is in the range of 85:15 to 65:35; and (b) a suitable carrier. wherein an emulsion type composition is excluded for therapeutic administration comprising: a) at least one phosphate derivative of a monoelectronic transfer agent; b) at least one phosphate derivative of a dielectronic transfer agent; where the electronic transfer agent is selected from the group consisting of hydroxychromans, stumps and tocotrienols in enantiomeric and racemic forms; quinoles which are the reduced forms of vitamin K1 and ubiquinone; and hydroxycarotenoids; and where the molar ratio between the phosphate derivative of the monoelectronic transfer agent and the phosphate derivative of the dielectronic transfer agent is in the range of 85:15 to 65:35; and c) a suitable carrier. |
| priorityDate | 2000-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.